Back to Search Start Over

Could be FOXO3a, miR-96-5p and miR-182-5p useful for Brazilian women with luminal A and triple negative breast cancers prognosis and target therapy?

Authors :
Mendes DCC
Filho CMCC
Garcia N
Ricci MD
Soares JM Júnior
Carvalho KC
Baracat EC
Source :
Clinics (Sao Paulo, Brazil) [Clinics (Sao Paulo)] 2023 Jan 19; Vol. 78, pp. 100155. Date of Electronic Publication: 2023 Jan 19 (Print Publication: 2023).
Publication Year :
2023

Abstract

FOXO3a dysregulation is frequently implicated in tumorigenesis, and its inhibition can occur by several molecular mechanisms. Among these, post-transcriptional suppression by miRNAs has been associated with various cancers initiation. Here, we assessed the expression profiles of the most relevant miRNAs for breast tumorigenesis, using Luminal A (LA) and Triple-Negative (TN) breast cancer from Brazilian patients, by the quantitative real time-PCR method. Their potential prognostic role for the patients was also evaluated. We identified the miRNAs miR-96-5p and miR-182-5p, de-scribed as negative regulators of FOXO3A, with differential expression both in LA and TN tumors when compared to normal tissue. The miR-96-5p and miR-182-5p miRNAs were upregulated in LA (7.82 times, p < 0.005; 6.12 times, p < 0.005, respectively) and TN breast cancer samples (9.42 times, p < 0.0001; 8.51 times, p < 0.0001) compared to normal tissues. The samples with higher miR-96-5p and miR-182-5p expression (FR ≥ 4) were submitted for FOXO3a immunostaining. Reduced protein detection was observed in all of the tumors compared to normal tissues. The most prominent miRNA expression and FOXO3a protein suppression were observed in TN samples (p < 0.001), indicating the relevant role of these molecules in this tumor biology and clinical behavior. Our results corroborate the literature regarding to the relevance of FOXO3a in the breast cancer, and they open new perspectives for alternative target therapy options for Brazilian patients expressing both FOXO3a and its regulatory miRNAs.<br />Competing Interests: Declaration of Competing Interest The authors declare no conflicts of interest.<br /> (Copyright © 2022 HCFMUSP. Published by Elsevier España, S.L.U. All rights reserved.)

Details

Language :
English
ISSN :
1980-5322
Volume :
78
Database :
MEDLINE
Journal :
Clinics (Sao Paulo, Brazil)
Publication Type :
Academic Journal
Accession number :
36681070
Full Text :
https://doi.org/10.1016/j.clinsp.2022.100155